Yeah good question, my feeling is that it will heavily depend on how the patients are screened and thus selected.
When PAR asks for patients it wont just be any old random people (the first 1100 for instance), they will need to meet some certain criteria at leats for the bulk...there may be some selection though (see at end of this post)
Ok so Mozz, what was the criteria for phase 2 OA? Glad you asked:
1) Kellgren lawrence score had to be 2, 3 or 4.
(Rating of '1' is too low in terms of current OA), this is a world famous scale rating for degree of OA. Our drug has most effect for > 2)
2) Pain related to OA for at least 6 months
3) BMI could only be between 18 to 35 kg/m2
4) Females must be of non child-bearing potential
5) Presence of BMEL's which were to be confirmed on screening via MRI
6) Age must be within 40 - 75 years of age
7) No evidence of increased bleeding in the past
8) No HIV or Hep B/C in the past
9) No Allergies to PPS
10) No other potential safety jepordising events (eg respiratory/heart/etc etc problems)
SO, you can see it was a very deliberate selection. For Phase 3 it may be different in that they may actually want some of these groups to be deliberately included to test out these previously excluded patients. They may divvy the groups up as the whole point of 3rd phase is to test for safety at scale. If iPPS is show to have AE's for anyone that has heart problems in the past or are older than 70 then this must be found out, may not be a show stopper but further investigation/testing and perhaps if its not lethal then approritae warnings would need to be considered based on the rest of the results for the rest of the Trial 3 patient population.
- Mozz
- Forums
- ASX - By Stock
- PAR
- PharmD price target fun
PharmD price target fun, page-77
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.29M |
Open | High | Low | Value | Volume |
19.5¢ | 20.5¢ | 19.0¢ | $156.2K | 795.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 152244 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 25584 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 152244 | 0.195 |
15 | 319964 | 0.190 |
5 | 127136 | 0.185 |
13 | 1098785 | 0.180 |
8 | 170525 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 25584 | 1 |
0.205 | 34294 | 2 |
0.210 | 54946 | 3 |
0.215 | 252000 | 1 |
0.220 | 17066 | 3 |
Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online